Publicaciones en las que colabora con Elisa Garbayo Atienza (19)

2021

  1. Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction

    Acta Biomaterialia, Vol. 126, pp. 394-407

  2. Optimization of a GDNF production method based on Semliki Forest virus vector

    European Journal of Pharmaceutical Sciences, Vol. 159

2019

  1. Long-term engraftment of human cardiomyocytes combined with biodegradable microparticles induces heart repair

    Journal of Pharmacology and Experimental Therapeutics, Vol. 370, Núm. 3, pp. 761-771

2016

  1. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

  2. Catheter-based intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion

    Scientific Reports, Vol. 6

2014

  1. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration

    Journal of Controlled Release, Vol. 173, Núm. 1, pp. 132-139

2013

  1. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system

    International Journal of Pharmaceutics, Vol. 440, Núm. 1, pp. 19-26

  2. Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

    Maturitas, Vol. 76, Núm. 3, pp. 272-278

2012

  1. Brain drug delivery systems for neurodegenerative disorders

    Current Pharmaceutical Biotechnology, Vol. 13, Núm. 12, pp. 2388-2402

2011

  1. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 10, pp. 1943-1947

2010

  1. Production of highly pure human glycosylated GDNF in a mammalian cell line

    International Journal of Pharmaceutics, Vol. 385, Núm. 1-2, pp. 6-11

  2. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model

    Journal of Controlled Release, Vol. 147, Núm. 1, pp. 30-37

2009

  1. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease

    Journal of Controlled Release, Vol. 135, Núm. 2, pp. 119-126

2008

  1. Controlled drug delivery to the brain: an overview

    Handbook of particulate drug delivery (American Scientific Publishers), pp. 121 - 142

  2. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, Núm. 3, pp. 844-851

2007

  1. Microencapsulación de factores neurotróficos: Aplicación al tratamiento de la enfermedad de Parkinson

    Mapfre Medicina, Vol. 18, Núm. 4, pp. 240-248

  2. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

    International Journal of Pharmaceutics, Vol. 344, Núm. 1-2, pp. 9-15

2006

  1. Expresión y purificación de GDNF para su microencapsulación y aplicación en la enfermedad de Parkinson

    Mapfre Medicina, Vol. 17, Núm. 3, pp. 166-171

  2. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 3, pp. 325-335